New Addition to the UG Series: Comprehensively Enhancing Coagulation Diagnostic Capabilities for Small and Medium-sized Laboratories

From March 21–23, 2026, the 23rd China Association of Clinical Laboratory Practice (CACLP) Expo was held at the Xiamen International Expo Center. On the first day of the exhibition, Shanghai Sun Biotech held a new product launch event at its booth, officially introducing the newest member of the UG series—the UG1200 Fully Automated Coagulation Analyzer. Accompanied by a comprehensive range of specialized coagulation reagents, this product provides small and medium-sized laboratories with more economical and high-quality coagulation testing solutions, bolstering the diagnostic and treatment capabilities for thrombosis and hemostasis at the grassroots level.

UG1200: Driving the Upgrade of Coagulation Diagnostic Capabilities in Small and Medium-sized Laboratories

There is a distinct structural disparity in coagulation laboratory testing capabilities. High-end coagulation analyzers are primarily concentrated in tertiary hospitals, while secondary and lower-level medical institutions—which handle a large volume of primary diagnostic tasks—face constraints in equipment configuration and capital investment. As a result, their coagulation testing has long remained at the routine screening level, making it difficult to meet growing clinical demands.

The newly released UG1200 provides a solution to this dilemma. Descended from the same lineage as the UG2500, it inherits the optical-magnetic hybrid detection technology and platelet aggregation assessment functions. It supports core capabilities such as automated APTT mixing studies, automated factor parallel assays, and micro-volume blood sampling, extending high-end coagulation testing capabilities to small and medium-sized laboratories. With stable and precise performance, excellent anti-interference capability, a compact design, and a high degree of automation, the UG1200 is set to drive the overall enhancement of coagulation testing capabilities in small and medium-sized medical institutions.

Full Coverage of Domestic Specialty Coagulation Reagents: Facilitating Standardized Management of Bleeding and Thrombotic Diseases

For a long time, specialty coagulation reagents in China have been dominated by imported brands, which come with higher operational costs. In some regions, the mismatch between reimbursement rates and procurement costs has restricted the reasonable implementation of these diagnostic projects.Addressing actual clinical needs, Shanghai Sun Biotech has developed a comprehensive reagent menu including coagulation factors (II, V, VII, VIII, IX, X, XI, XII), Protein C, Protein S, Antithrombin III (AT-III), Lupus Anticoagulant (LA), and Anti-Xa activity assays. This builds a systematic testing framework covering routine screening, coagulation factor assays, thrombophilia diagnosis, and anticoagulant monitoring. The cost-effective advantage of domestic reagents allows more medical institutions to truly implement testing projects with clear clinical value, thereby promoting the standardized management of bleeding and thrombotic diseases.

With the launch of the UG1200 and its specialty reagents, Shanghai Sun Biotech has established a complete coagulation testing solution covering everything from small to ultra-large laboratories, providing strong support for the balanced development of laboratory capabilities within the tiered healthcare system. We cordially invite experts and industry colleagues to visit our booth to explore new opportunities in the development of coagulation testing technology!